Evaluation of Nevisense as Support Tool for the Diagnose of Keratinocyte Skin Cancer
ConditionKeratinocyte Skin Cancer
Trial statusRecruiting
Trial phaseNot applicable
Trial typeInterventional
Biological sexAll
Age18+
SponsorSciBase AB
About this trial
This is a prospective study to assess efficacy of the Nevisense device in identifying keratinocyte skin cancer (KC) in patients suspected of having skin cancer based on the initial physician's assessment.
All skin lesions with a suspicion of Basal cell carcinoma (BCC), Invasive Squamos cell Carcinoma (iSCC), Bowen's disease (BD) or actinic keratosis (AK) and destined for excision or biopsy for further histopathological analysis will be considered for inclusion in the study.
Eligibility criteria
Qualifiers
All male or female patients of any ethnicity, ≥ 18 years with skin lesions of a clinical uncertain diagnosis suspicious for KC (such as BCC, iSCC, BD or AK)
Disqualifiers
Metastases of recurrent lesions
Lesion located on acral skin, e.g. sole or palm
Lesion located on areas of scars, crusts, psoriasis or similar skin conditions
Lesion on hair-covered areas, e.g. scalp, beards, moustaches
Trial design
Treatments tested in this trial
- Nevisense
Treatment groups
150 Participants
are divided into 1 treatment groupSponsors and collaborators
SciBase AB
Lead sponsor
CentroDerm GmbH
Sponsor institution
Source ClinicalTrials.gov